Argos Therapeutics, Inc. Share Price

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

24/19/24	Argos Therapeutics, Inc. Went Out of Business	CI
24/19/24	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation: Argos Therapeutics, Inc.

Market Cap	3L 3L 3L 2L 4L 3.02Cr 4L 30.1L 11.81L 1.52Cr 11.93L 11.67L 5.01Cr	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	45.85L 39.66L 37.04L 33.98L 63.9L 44Cr 64.92L 4.35Cr 1.71Cr 22Cr 1.72Cr 1.68Cr 72Cr	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news : Argos Therapeutics, Inc.

24/19/24	Argos Therapeutics, Inc. Went Out of Business	CI
24/19/24	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
30/19/30	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
21/19/21	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
15/19/15	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
13/19/13	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
23/19/23	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
22/19/22	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
22/19/22	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
22/19/22	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
20/18/20	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
06/18/06	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
03/18/03	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
ARGSQ Stock

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	6L
REGENERON PHARMACEUTICALS, INC.	+1.59%	+2.85%	+40.11%	+1.24%	7.83TCr
SAMSUNG BIOLOGICS CO.,LTD.	+2.77%	+4.78%	-1.65%	+27.62%	5.11TCr
UCB	-0.84%	+0.09%	+20.92%	+179.15%	4.92TCr
CSL LIMITED	-0.13%	+7.42%	-50.22%	-49.58%	4.47TCr
BIOGEN INC.	+0.80%	+2.46%	+62.77%	-23.33%	3.07TCr
INCYTE CORPORATION	+1.84%	+0.87%	+54.17%	+85.73%	2.44TCr
MODERNA, INC.	+9.86%	+7.94%	+122.36%	-41.53%	2.36TCr
INNOVENT BIOLOGICS, INC.	+4.29%	+9.40%	+3.77%	+226.51%	2.1TCr
SWEDISH ORPHAN BIOVITRUM AB	+1.66%	-3.70%	+65.40%	+123.91%	1.66TCr
Average	+2.18%	+3.05%	+35.29%	+58.86%	3.4TCr
Weighted average by Cap.	+1.88%	+4.29%	+26.93%	+45.10%

	2016	2017
Net sales	9L 8L 8L 7L 13.18L 9Cr 13.39L 89.6L 35.17L 4.51Cr 35.5L 34.73L 15Cr	18.99L 16.43L 15.34L 14.07L 26.47L 18Cr 26.89L 1.8Cr 70.65L 9.06Cr 71.33L 69.76L 30Cr
Net income	-5.3Cr -4.59Cr -4.28Cr -3.93Cr -7.39Cr -504.68Cr -7.51Cr -50Cr -20Cr -252.96Cr -20Cr -19Cr -836.26Cr	-4.06Cr -3.51Cr -3.28Cr -3.01Cr -5.66Cr -386.18Cr -5.75Cr -38Cr -15Cr -193.56Cr -15Cr -15Cr -639.92Cr
Net Debt	-1.31Cr -1.13Cr -1.06Cr -97.14L -1.83Cr -124.76Cr -1.86Cr -12Cr -4.88Cr -63Cr -4.92Cr -4.81Cr -206.73Cr	42.67L 36.91L 34.47L 31.62L 59.48L 41Cr 60.42L 4.04Cr 1.59Cr 20Cr 1.6Cr 1.57Cr 67Cr

Argos Therapeutics, Inc. Share Price

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation: Argos Therapeutics, Inc.

Latest news : Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile